Compared with eGFRcr, a 30% lower eGFRcys was associated with higher rates of all-cause mortality, cardiovascular events, and kidney disease.
To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...
The phase 2 EXPLORE-CKD trial is examining the efficacy and safety of lorundrostat in addition to SGLT2 inhibitors in patients with hypertension and CKD with albuminuria.
A new tool can predict individualized probability of survival with conservative management (CM) versus dialysis transition ...
Medpage Today on MSN
Drug Combo Lowers Albuminuria in High-Risk Chronic Kidney Disease
Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...
Intensive blood pressure lowering yielded significant net benefits among patients with chronic kidney disease.
4d
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback